y 27632 has been researched along with Granulocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basbous, S; Bourmeyster, N; Brizard, F; Gombert, JM; Guilhot, F; Herbelin, A; Levescot, A; Piccirilli, N; Roy, L | 1 |
| Adams, J; Burthem, J; Lucas, GS; Mottram, R; Rees-Unwin, K; Spooncer, E; Whetton, AD | 1 |
2 other study(ies) available for y 27632 and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
Topics: Amides; Antigens, CD1d; Cell Differentiation; Dendritic Cells; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunity, Innate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cells; Natural Killer T-Cells; Protein Kinase Inhibitors; Pyridines; rho-Associated Kinases | 2016 |
The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Antigens, CD34; Benzamides; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; rho-Associated Kinases; Stem Cells; Tumor Cells, Cultured | 2007 |